Sarepta Therapeutics Total Assets 2006-2021 | SRPT

Sarepta Therapeutics total assets from 2006 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Sarepta Therapeutics total assets for the quarter ending September 30, 2021 were $2.662B, a 4.26% decline year-over-year.
  • Sarepta Therapeutics total assets for 2020 were $2.985B, a 63.74% increase from 2019.
  • Sarepta Therapeutics total assets for 2019 were $1.823B, a 11.01% increase from 2018.
  • Sarepta Therapeutics total assets for 2018 were $1.642B, a 25.54% increase from 2017.
Sarepta Therapeutics Annual Total Assets
(Millions of US $)
2020 $2,985
2019 $1,823
2018 $1,642
2017 $1,308
2016 $424
2015 $274
2014 $295
2013 $292
2012 $205
2011 $54
2010 $46
2009 $60
2008 $26
2007 $39
2006 $41
2005 $56
Sarepta Therapeutics Quarterly Total Assets
(Millions of US $)
2021-09-30 $2,662
2021-06-30 $2,759
2021-03-31 $2,765
2020-12-31 $2,985
2020-09-30 $2,781
2020-06-30 $2,883
2020-03-31 $2,947
2019-12-31 $1,823
2019-09-30 $1,702
2019-06-30 $1,748
2019-03-31 $1,964
2018-12-31 $1,642
2018-09-30 $1,183
2018-06-30 $1,247
2018-03-31 $1,300
2017-12-31 $1,308
2017-09-30 $800
2017-06-30 $450
2017-03-31 $512
2016-12-31 $424
2016-09-30 $487
2016-06-30 $204
2016-03-31 $213
2015-12-31 $274
2015-09-30 $185
2015-06-30 $232
2015-03-31 $243
2014-12-31 $295
2014-09-30 $319
2014-06-30 $337
2014-03-31 $275
2013-12-31 $292
2013-09-30 $304
2013-06-30 $184
2013-03-31 $193
2012-12-31 $205
2012-09-30 $53
2012-06-30 $42
2012-03-31 $47
2011-12-31 $54
2011-09-30 $61
2011-06-30 $75
2011-03-31 $47
2010-12-31 $46
2010-09-30 $51
2010-06-30 $49
2010-03-31 $53
2009-12-31 $60
2009-09-30 $65
2009-06-30 $33
2009-03-31 $37
2008-12-31 $26
2008-09-30 $30
2008-06-30 $33
2008-03-31 $35
2007-12-31 $39
2007-09-30 $27
2007-06-30 $31
2007-03-31 $35
2006-12-31 $41
2006-09-30 $47
2006-06-30 $52
2006-03-31 $58
2005-12-31 $56
2005-09-30 $40
2005-06-30 $41
2005-03-31 $46
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $6.954B $0.540B
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma, Inc., is headquartered in Bothell, Washington.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $121.281B 7.66
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.681B 21.48
Biohaven Pharmaceutical Holding (BHVN) United States $7.357B 0.00
Arcus Biosciences (RCUS) United States $3.170B 0.00
Emergent Biosolutions (EBS) United States $2.265B 8.14
Myovant Sciences (MYOV) United Kingdom $1.741B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.500B 0.00
Zymeworks (ZYME) Canada $0.902B 0.00
Ambrx Biopharma (AMAM) United States $0.391B 0.00
SQZ Biotechnologies (SQZ) United States $0.337B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.95